Biogen prices new ALS treatment at $14,230 per vial
Biogen Inc. (BIIB) has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerated approval by the U.S. Food and Drug Administration last week. The treatment is administered through a spinal injection. The price tag of $14,230 is the wholesale acquisition cost, the spokesperson said. Biogen stock was down 1.2% Tuesday, but has gained 11% in the year to date, while the S&P 500 has gained 8.6%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-02-23 1215ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
Microsoft Earnings Beat Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth
-
10 Best Blue-Chip Stocks to Buy for the Long Term
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
ServiceNow Earnings: Strong Quarter With In-Line Guidance and Increasingly Attractive Valuation
-
Ford Earnings: Pro Continues to Impress While EV Costs Are Contained
-
Boeing Earnings: Paying for Mistakes Made Long Ago, Taking Back the Factory Floor
-
Meta Earnings: Stock Now Fairly Valued After Latest Selloff